Skip to main content
Kinarus Therapeutics Holding AG logo

Kinarus Therapeutics Holding AG — Investor Relations & Filings

Ticker · KNRS ISIN · CH1330780979 LEI · 506700VDL70GGMHR5758 SW Manufacturing
Open in API
Filings indexed 68 across all filing types
Latest filing 2023-07-12 Board/Management Inform…
Country CH Switzerland
Listing SW KNRS

About Kinarus Therapeutics Holding AG

https://www.curatis.com/

Formerly Kinarus Therapeutics Holding AG, the company now operates as Curatis Holding AG, a specialty pharmaceutical company focused on the acquisition, development, and commercialization of innovative medicines for rare and specialty care diseases. The company's operations are divided into two segments. The distribution business acquires, licenses, and distributes third-party medicines for orphan and specialty diseases. The development business advances a pipeline of novel drug candidates, prioritizing compounds with existing safety and efficacy data to accelerate development. Key development programs target conditions such as peritumoral brain edema, severe migraine with aura, and medication overuse headache.

Recent filings

Filing Released Lang Actions
Kinarus Therapeutics Announces Personnel Changes
Board/Management Information Classification · 100% confidence The document is explicitly titled a 'MEDIA RELEASE' and announces that the interim-CFO is leaving the company. This directly relates to changes in senior management personnel. Based on the provided definitions, the category 'Board/Management Information (Code: MANG)' is the most appropriate fit for announcements of changes in senior management.
2023-07-12 English
Kinarus Therapeutics Shareholders Approve All Board Proposals at the 2023 Annual General Meeting
AGM Information Classification · 99% confidence The document is explicitly titled as a 'MEDIA RELEASE' announcing that 'Kinarus Therapeutics Shareholders Approve All Board Proposals at the 2023 Annual General Meeting'. It details the outcomes of the meeting, including the approval of the 2022 Annual Report, re-election of board members, and compensation votes. This content directly relates to the proceedings and results of the Annual General Meeting (AGM). Therefore, the most appropriate classification is AGM Information (AGM-R). Although it mentions the approval of the Annual Report, the document itself is the announcement of the AGM results, not the full 10-K report.
2023-06-29 English
Kinarus Therapeutics signed subordinated bridge loans to ensure further liquidity
Capital/Financing Update Classification · 98% confidence The document is an 'Ad hoc announcement pursuant to Art. 53 LR' dated June 27, 2023. The core content discusses the signing of 'subordinated bridge loan agreements with existing shareholders to ensure further liquidity' pending a larger convertible loan investment. This action directly relates to the company's financing activities and capital structure management. Based on the provided definitions, the most appropriate classification is 'Capital/Financing Update' (CAP). It is not a full report (10-K, IR), an earnings release (ER), or a management discussion (MDA), but a specific announcement about securing short-term funding.
2023-06-27 English
Kinarus Therapeutics Publishes Invitation to the 2023 Annual General Meeting
Report Publication Announcement Classification · 99% confidence The document explicitly states: 'Kinarus Therapeutics Publishes Invitation to the 2023 Annual General Meeting' and provides details about the upcoming AGM date, location, and access to the invitation. This directly relates to the Annual General Meeting (AGM). Although it mentions the annual report is available for download, the primary purpose of this specific press release is to announce the invitation and details for the AGM itself. Therefore, the most appropriate classification is AGM Information (AGM-R). The document length (3111 chars) is short, but the content is a direct announcement about the meeting, not just a notice that a report is attached (RPA).
2023-06-02 English
Annual financial report 2022
Annual Report Classification · 100% confidence The document is explicitly titled 'Annual Report 2022' and contains comprehensive sections including a Letter to Shareholders, Business Review, Corporate Governance, Compensation Report, and Consolidated Financial Statements. It covers the company's full fiscal year performance, strategy, and financial position, fitting the definition of a 10-K (Annual Report). FY 2022
2023-05-31 English
Kinarus Therapeutics Provides Strategic Update
Regulatory Filings Classification · 95% confidence The document is a media release from Kinarus Therapeutics providing a strategic update regarding their clinical trials and financial focus. It discusses the status of their drug candidate KIN001, the discontinuation of one study, the continuation of another, and the intent to raise funds for future trials. This type of corporate communication, which provides updates on business strategy and financing efforts without being a formal financial report or a specific regulatory filing, is best classified as a Regulatory Filing (RNS) under the provided schema.
2022-11-04 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.